On Tuesday, Sotera Health hit an important technical milestone, with its Relative Strength (RS) Rating climbing into the 90-plus percentile with an upgrade to 91, a rise from 86 the day before.
This unique rating measures technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price performance over the trailing 52 weeks matches up against other publicly traded companies.
Decades of market research reveals that the stocks that go on to make the biggest gains tend to have an RS Rating of over 80 at the beginning of a new run.
Here Are 3 Keys For Successful Stock Investing
Is Sotera Health Stock A Buy?
Sotera Health stock is building a cup without handle with a 17.44 buy point. See if the medical stock can clear the breakout price in heavy trading. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
The medical services provider showed -5% EPS growth last quarter, while sales growth came in at 8%.
Sotera Health stock earns the No. 2 rank among its peers in the Medical-Services industry group. Castle Biosciences is the No. 1-ranked stock within the group.
